AU2004230244B2 - S. pneumoniae antigens - Google Patents

S. pneumoniae antigens Download PDF

Info

Publication number
AU2004230244B2
AU2004230244B2 AU2004230244A AU2004230244A AU2004230244B2 AU 2004230244 B2 AU2004230244 B2 AU 2004230244B2 AU 2004230244 A AU2004230244 A AU 2004230244A AU 2004230244 A AU2004230244 A AU 2004230244A AU 2004230244 B2 AU2004230244 B2 AU 2004230244B2
Authority
AU
Australia
Prior art keywords
seq
pneumoniae
antibody
nucleic acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004230244A
Other languages
English (en)
Other versions
AU2004230244A1 (en
Inventor
Shailesh Dewasthaly
Markus Hanner
Andreas Meinke
Eszter Nagy
Ulrike Stierschneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of AU2004230244A1 publication Critical patent/AU2004230244A1/en
Application granted granted Critical
Publication of AU2004230244B2 publication Critical patent/AU2004230244B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004230244A 2003-04-15 2004-04-15 S. pneumoniae antigens Ceased AU2004230244B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03450087 2003-04-15
EP03450087.6 2003-04-15
PCT/EP2004/003984 WO2004092209A2 (en) 2003-04-15 2004-04-15 S. pneumoniae antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011218655A Division AU2011218655A1 (en) 2003-04-15 2011-08-30 S. Pneumoniae Antigens

Publications (2)

Publication Number Publication Date
AU2004230244A1 AU2004230244A1 (en) 2004-10-28
AU2004230244B2 true AU2004230244B2 (en) 2011-09-22

Family

ID=33186037

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004230244A Ceased AU2004230244B2 (en) 2003-04-15 2004-04-15 S. pneumoniae antigens

Country Status (7)

Country Link
US (3) US7635487B2 (OSRAM)
EP (11) EP1615950A2 (OSRAM)
JP (3) JP2007525157A (OSRAM)
CN (2) CN1774447B (OSRAM)
AU (1) AU2004230244B2 (OSRAM)
CA (1) CA2522238A1 (OSRAM)
WO (1) WO2004092209A2 (OSRAM)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
CN1909921B (zh) * 2003-11-10 2012-09-26 Uab研究基金会 减少细菌携带和中枢神经系统侵害的组合物及其使用方法
EP2059807B1 (en) * 2006-08-17 2013-02-20 The UAB Research Foundation Diagnosing pneumococcal pneumonia
WO2008039838A2 (en) * 2006-09-27 2008-04-03 St. Jude Children's Research Hospital Synthetic streptococcus pneumoniae vaccine
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
EP2164957B1 (en) * 2007-05-23 2017-07-12 The UAB Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
WO2008146164A2 (en) * 2007-05-25 2008-12-04 Novartis Ag Streptococcus pneumoniae pilus antigens
AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN105044337A (zh) * 2008-02-01 2015-11-11 圣诺菲·帕斯图尔有限公司 用于诊断肺炎链球菌的试验
DK2268618T3 (en) 2008-03-03 2015-08-17 Novartis Ag Compounds and compositions as TLR aktivitetsmodulatorer
CA2718473A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
EP2108656A1 (en) * 2008-03-19 2009-10-14 Beninati, Concetta Antigenic protein fragments of streptococcus pneumoniae
US8348429B2 (en) 2008-03-27 2013-01-08 Doheny Eye Institute Optical coherence tomography device, method, and system
US11839430B2 (en) 2008-03-27 2023-12-12 Doheny Eye Institute Optical coherence tomography-based ophthalmic testing methods, devices and systems
WO2009143483A2 (en) * 2008-05-22 2009-11-26 The Board Of Regents Of The University Of Texas System PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
WO2010009450A1 (en) 2008-07-18 2010-01-21 Doheny Eye Institute Optical coherence tomography device, method, and system
ES2352704B1 (es) * 2008-08-08 2012-06-14 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)(Titular al 80%) Secuencia de nucleotido y proteina b-galactosidasa de streptococcus mitis, procedimiento de obtencion y sus aplicaciones.
WO2010025584A1 (zh) * 2008-09-04 2010-03-11 Wang Lei 表达发卡rna的dna分子及其构建方法和应用
WO2010029546A2 (en) * 2008-09-11 2010-03-18 Ben Gurion University Of The Negev Research And Development Authority Compositions and methods for treating s.pneumoniae infection
ATE523204T1 (de) 2009-02-16 2011-09-15 Karlsruher Inst Technologie Cd44v6-peptide als bakterielle infektionsinhibitoren
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2440245B1 (en) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
CA2803061A1 (en) * 2009-06-29 2011-01-20 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
AU2010293902A1 (en) 2009-09-10 2012-03-22 Novartis Ag Combination vaccines against respiratory tract diseases
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
WO2011112906A2 (en) * 2010-03-12 2011-09-15 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
EP2549990A1 (en) 2010-03-23 2013-01-30 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
SG10201600435UA (en) 2011-01-20 2016-02-26 Genocea Biosciences Inc Vaccines And Compositions Against Streptococcus Pneumoniae
JP6366501B2 (ja) 2011-05-11 2018-08-01 ザ チルドレンズ メディカル センター コーポレーション 修飾ビオチン結合タンパク質、その融合タンパク質、および用途
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
MX2014010011A (es) * 2012-02-24 2014-09-08 Novartis Ag Proteinas y composiciones de pilus.
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
RU2510281C2 (ru) 2012-06-22 2014-03-27 Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп") ВАКЦИНА ПРОТИВ ПНЕВМОНИИ, ВЫЗЫВАЕМОЙ Streptococcus pneumoniae, НА ОСНОВЕ ГИБРИДНОГО БЕЛКА
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
ES2959258T3 (es) 2013-02-07 2024-02-22 Childrens Medical Center Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas
US10772497B2 (en) 2014-09-12 2020-09-15 Envision Diagnostics, Inc. Medical interfaces and other medical devices, systems, and methods for performing eye exams
US9226856B2 (en) 2013-03-14 2016-01-05 Envision Diagnostics, Inc. Inflatable medical interfaces and other medical devices, systems, and methods
JPWO2016204265A1 (ja) * 2015-06-18 2018-06-14 一般財団法人阪大微生物病研究会 肺炎球菌補体依存性殺菌能測定方法
US11039741B2 (en) 2015-09-17 2021-06-22 Envision Diagnostics, Inc. Medical interfaces and other medical devices, systems, and methods for performing eye exams
WO2017190087A1 (en) 2016-04-30 2017-11-02 Envision Diagnostics, Inc. Medical devices, systems, and methods for performing eye exams and eye tracking
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
WO2018183475A1 (en) 2017-03-28 2018-10-04 Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
ES2967001T3 (es) 2017-06-23 2024-04-25 Affinivax Inc Composiciones inmunogénicas
EP3752182B1 (en) 2018-02-12 2024-05-15 Inimmune Corporation Toll-like receptor ligands
GB201807380D0 (en) * 2018-05-04 2018-06-20 Karlsson Roger Biomarkers for detecting microbial infection
WO2020056202A1 (en) 2018-09-12 2020-03-19 Affinivax, Inc. Multivalent pneumococcal vaccines
JP7535791B2 (ja) 2018-09-12 2024-08-19 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌融合タンパク質ワクチン
RU2701733C1 (ru) * 2018-12-14 2019-10-01 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Живая вакцина на основе штамма пробиотиков ENTEROCOCCUS FAECIUM L3 для профилактики инфекции, вызванной STREPTOCOCCUS PNEUMONIE
CN111748535B (zh) * 2019-03-28 2022-07-05 安徽华恒生物科技股份有限公司 一种丙氨酸脱氢酶突变体及其在发酵生产l-丙氨酸中的应用
KR20230117105A (ko) 2020-11-04 2023-08-07 엘리고 바이오사이언스 큐티박테리움 아크네스 재조합 파지, 그의 제조 방법 및 용도
GB202100097D0 (en) * 2021-01-05 2021-02-17 Univ Liverpool Novel composition
KR20240099160A (ko) 2021-09-09 2024-06-28 아피니백스, 인크. 다가 폐렴구균 백신
TW202413403A (zh) * 2022-06-07 2024-04-01 北京大學第一醫院 包含IgA蛋白酶截短體的融合蛋白及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049721A2 (en) * 1999-12-30 2001-07-12 Bristol-Myers Squibb Company Bacterial genes and proteins that are essential for cell viability and their uses
WO2002077021A2 (en) * 2001-03-27 2002-10-03 Chiron Srl. Streptococcus pneumoniae proteins and nucleic acids

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US40000A (en) 1863-09-15 Improvement in sewing-machines
US4609231A (en) 1984-12-24 1986-09-02 Perfectdata Corporation Floppy diskette storage container
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
DE59109269D1 (de) 1990-06-28 2005-12-15 Hoechst Ag Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
DE69232871T2 (de) 1991-06-24 2003-05-08 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Polypeptide des hepatitis c-virus (hiv)
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
CZ394297A3 (cs) * 1995-06-07 1998-04-15 Biochem Vaccines Inc. Streptokokové proteiny teplotního šoku ze skupiny HSP70
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6605713B1 (en) 1996-08-30 2003-08-12 Jens Peter Furste Mirror-symmetrical selection and evolution of nucleic acids
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE69739981D1 (de) * 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
JP2001510989A (ja) * 1996-11-01 2001-08-07 スミスクライン・ビーチャム・コーポレイション 新規コーディング配列
US6071724A (en) * 1996-12-13 2000-06-06 Eli Lilly And Company Streptococcus pneumoniaegene sequence era
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP1144640A3 (en) * 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
EP1100921B1 (en) * 1998-07-27 2007-05-02 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
US6951652B2 (en) * 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
WO2000029434A2 (en) * 1998-11-19 2000-05-25 St. Jude Children's Research Hospital PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
CN100398653C (zh) * 1998-12-23 2008-07-02 益得生物医学公司 新颖的链球菌抗原
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
DE60130877T2 (de) 2000-04-14 2008-07-17 Intercell Ag Modifizierte peptide enthaltende pharmazeutische präparationen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
WO2002005448A1 (en) 2000-07-10 2002-01-17 Telefonaktiebolaget Lm Ericsson (Publ) Resource management in uncoordinated frequency hopping system
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AU1412702A (en) 2000-10-27 2002-05-06 Chiron Spa Nucleic acids and proteins from streptococcus groups a and b
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US7482012B2 (en) 2001-02-21 2009-01-27 Id Biomedical Corporation Streptococcus pyogenes polypeptides and corresponding DNA fragments
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2002083859A2 (en) 2001-04-13 2002-10-24 Wyeth Surface proteins of streptococcus pyogenes
EP2277897A1 (en) * 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
FR2824074A1 (fr) 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
EP1450821A1 (en) 2001-12-07 2004-09-01 Intercell AG Immunostimulatory oligodeoxynucleotides
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049721A2 (en) * 1999-12-30 2001-07-12 Bristol-Myers Squibb Company Bacterial genes and proteins that are essential for cell viability and their uses
WO2002077021A2 (en) * 2001-03-27 2002-10-03 Chiron Srl. Streptococcus pneumoniae proteins and nucleic acids

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BETHE, G. et al., FEMS Microbiology Letters, 2001, vol. 205, pages 99-104 *
HOSKINS, J. et al., Journal of Bacteriology, 2001, vol. 183, pages 5709-5717 *
NABORS, G.S. et al., Vaccine, 2000, vol. 18, pages 1743-1754 *
OVERWEG, K. et al., Infection and Immunity, 2000, vol. 68, pages 4180-4188 *
TETTELIN, H. et al., Science, 2001, vol. 293, pages 498-506 *
WIZEMANN, T.M. et al., Infection and Immunity, 2001, vol. 69, pages 1593-1598 *

Also Published As

Publication number Publication date
US20100260790A1 (en) 2010-10-14
WO2004092209A2 (en) 2004-10-28
AU2004230244A1 (en) 2004-10-28
JP2012184236A (ja) 2012-09-27
EP2314719A1 (en) 2011-04-27
US20130136761A1 (en) 2013-05-30
JP2011004753A (ja) 2011-01-13
EP2298934A1 (en) 2011-03-23
CN1774447B (zh) 2011-04-06
WO2004092209A3 (en) 2004-12-09
EP2311989A1 (en) 2011-04-20
EP2311988A1 (en) 2011-04-20
CN1774447A (zh) 2006-05-17
EP2333114A1 (en) 2011-06-15
WO2004092209A9 (en) 2008-11-27
EP2336357A1 (en) 2011-06-22
US7635487B2 (en) 2009-12-22
EP2314718A1 (en) 2011-04-27
JP2007525157A (ja) 2007-09-06
US20060263846A1 (en) 2006-11-23
EP2311991A1 (en) 2011-04-20
CN102174534A (zh) 2011-09-07
HK1084958A1 (en) 2006-08-11
EP2311987A1 (en) 2011-04-20
CA2522238A1 (en) 2004-10-28
EP1615950A2 (en) 2006-01-18
EP2311990A1 (en) 2011-04-20
US8372411B2 (en) 2013-02-12

Similar Documents

Publication Publication Date Title
AU2004230244B2 (en) S. pneumoniae antigens
CA2413450C (en) Streptococcus antigens
JPH11513371A (ja) 肺炎球菌遺伝子、その一部、それ由来の発現産物、ならびに該遺伝子、該遺伝子の一部分、および該遺伝子産物の使用
US20110243978A1 (en) Enterococcus antigens
IL137921A (en) Proteins and polypeptides of group B streptococcus
US20040096973A1 (en) Environmentally regulated genes of Streptococcus suis
US6764823B2 (en) Antimicrobial methods and materials
AU2011218655A1 (en) S. Pneumoniae Antigens
US20100221277A1 (en) Chlamydia pneumoniae antigens
HK1084958B (en) S. pneumoniae antigens
AU2011236092A1 (en) Enterococcus Antigens

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired